ÂÜÀòÂÒÂ×

Melissa Deck has a comprehensive work experience in the biotechnology industry. Melissa is currently the Director of Platform at Liberate Bio since March 2023. Prior to that, they held the same position at Carver Biosciences, Inc. starting in March 2022.

Before their Director roles, Melissa worked as an Associate Director at Arbor Biotechnologies from November 2021 to April 2022. Melissa also had multiple positions at Gemini Therapeutics, including Associate Director of Gene Therapy from May 2021 to November 2021, Principal Scientist from February 2020 to May 2021, and Senior Scientist from October 2018 to February 2020.

Melissa's earlier experience includes working as a Scientist in Biology at Omega Therapeutics from July 2017 to September 2018, Senior Associate Scientist at Intellia Therapeutics, Inc. from June 2015 to July 2017, and Scientist I at Novartis Institutes for BioMedical Research from March 2014 to June 2015.

Their career started at AdvanDx, where they served as a Scientist II from May 2008 to March 2014. At AdvanDx, they were responsible for determining the feasibility of mRNA FISH detection of antibiotic resistance genes in Gram-negative bacteria, as well as creating and investigating the feasibility of a rapid susceptibility assay for Gram-negative bacteria in culture.

Melissa Deck obtained their Bachelor of Science degree in Biology, General from the University of Massachusetts Lowell, where they studied from 2004 to 2008.